JP Patent

JP6621761B2 — 薬学的に活性な化合物の固体形態

Assigned to エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト · Expires 2019-12-18 · 6y expired

What this patent protects

Patent listed against lazertinib-mesylate.

Drugs covered by this patent

Patent Metadata

Patent number
JP6621761B2
Jurisdiction
JP
Classification
—
Expires
2019-12-18
Drug substance claim
No
Drug product claim
No
Assignee
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.